Companies › Santen Pharmaceutical
2 active drug programs in 2 registered trials: 2 Phase 3; Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DE-117B Eye Drops Prostaglandin F (FP) receptor agonist | PTGFR | Phase 3 | Open Angle Glaucoma | – |
| STN1013800 ophthalmic solution | – | Phase 3 | Blepharoptosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06683651 | STN1013800 ophthalmic solution | Phase 3 | Blepharoptosis | Ophthalmology | Jun 2026 |
| NCT06666855 | DE-117B Eye Drops | Phase 3 | Open Angle Glaucoma | Ophthalmology | Aug 2026 |
YS Life Science SpyGlass Pharma ReGenTree Ocus Innovation Ireland Ocumension Therapeutics (Suzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.